Apitope Progresses Graves' Disease Treatment

DIEPENBEEK, Belgium, June 19, 2014 /PRNewswire/ --

Initiates Preclinical Development of Peptide Therapy

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that it has started preclinical development of its novel peptide therapy ATX-GD-459 for the treatment of Graves' disease.

Help employers find you! Check out all the jobs and post your resume.